These innovative molecules represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://lilianajvc971334.blog4youth.com/39680534/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide